Rationale for Categorizing Hydrocodone Combination Products as Schedule III

Published Online: Monday, January 20, 2014
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
 
This is the fifth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Ambulatory pharmacy practice will grow independent of community pharmacy practice, unless efforts are made to bring them closer together.
Fall and injuries in the elderly may be attributed to many popular prescription medications.
In this age group, such hospitalizations surged 104% between 2005 and 2011.
In 2012 alone, US health care providers wrote 82.5 opioid and 37.6 benzodiazepine prescriptions per 100 persons.
Latest Issues
$auto_registration$